| Literature DB >> 35897381 |
Piotr Rola1,2, Jan Jakub Kulczycki3, Adrian Włodarczak1,3, Mateusz Barycki2, Szymon Włodarczak3, Marek Szudrowicz3, Łukasz Furtan2, Artur Jastrzębski3, Maciej Pęcherzewski3, Maciej Lesiak4, Adrian Doroszko5.
Abstract
BACKGROUND: The unprotected calcified Left Main disease represents a high-risk subset for percutaneous coronary intervention (PCI), and it is associated with a higher number of periprocedural complications and an increased rate of in-stent thrombosis and restenosis. Adequate lesion preparation plays a crucial role in achieving a favorable PCI outcome. Rotational Atherectomy (RA) is a well-established plaque-modifying method; nevertheless, the data regarding the effectiveness of RA in LM diseases is scarce. Recently, the novel ShockWave-Intravascular-Lithotripsy(S-IVL) device has been introduced to the PCI armamentarium in order to modify the calcified plaque.Entities:
Keywords: cardiovascular diseases; coronary artery diseases (CAD); high-risk percutaneous coronary intervention; intravascular lithotripsy; left main; percutaneous coronary intervention (PCI); rotational atherectomy; shock wave intravascular lithotripsy device; vascular disease
Mesh:
Year: 2022 PMID: 35897381 PMCID: PMC9330248 DOI: 10.3390/ijerph19159011
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1A flow chart of the study protocol with inclusion and exclusion criteria. Abbreviations: LM—Left Main; PCI—percutaneous coronary intervention; S-IV—Shock Wave Intravascular Lithotripsy; RA—Rotational Atherectomy; LAD—Left Anterior Descending artery; Cx—Circumflex artery; MACE—major adverse cardiac events.
Figure 2Exemplary PCI procedures. S-IVL-related procedure (A–E). (A) Distal LM significant stenosis; (B) non-compliant 3.5 mm balloon under-expansion; (C) S-IVL 3.5 mm balloon inflation; (D) stenting with DES 4. 0 mm; and (E) final post PCI angiogram. RA-related procedure (F–L). (F) Distal LM critical stenosis with severe calcifications; (G) RA with burr 1.75 mm; (H) predilatation of LM with 3.5 mm non-compliant balloon; (I) pre-stenting angiogram; (J) LM/LAD stenting with DES 4.0 × 20 mm; (K) LM/LAD/Cx kissing balloons with non-compliant 3.5 mm/3.0 mm balloons; and (L) final post-PCI angiogram.
The baseline clinical characteristics of both study groups.
| Rotational | Shockwave | ||
|---|---|---|---|
| Age | 70.3 ± 9.1 | 72.1 ± 6.1 | 0.478 |
| Gender male (ratio) | 21 (72.4%) | 12 (80.0%) | 0.532 |
| Stable angina | 13 (44.8%) | 6 (40.0%) | 0.591 |
| Unstable angina | 6 (20.7%) | 2 (13.3%) | 0.511 |
| NSTEMI | 9 (31.0%) | 6 (40.0%) | 0.535 |
| STEMI | 1 (3.4%) | 1 (6.7%) | 0.561 |
| Diabetes mellitus | 16 (55.2%) | 10 (66.7%) | 0.487 |
| Chronic heart failure | 9 (31.0%) | 6 (40.0%) | 0.412 |
| Hypertension | 25 (86.2%) | 13 (86.7%) | 0.591 |
| Hyperlipidemia | 20 (68.9%) | 15 (100%) | 0.293 |
| Atrial Fibrillation | 5 (17.2%) | 5 (33.3%) | 0.248 |
| History of PCI | 16 (55.2%) | 7 (46.7%) | 0.544 |
| History of MI | 13 (44.8%) | 5 (33.3%) | 0.360 |
| History of CABG | 6 (20.7%) | 1 (6.7%) | 0.311 |
| COPD | 6 (20.7%) | 2 (13.3%) | 0.511 |
| Chronic kidney diseases | 13 (44.8%) | 6 (40.0%) | 0.519 |
Abbreviations: NSTEMI—no ST-Elevation Myocardial Infraction; STEMI—ST-Elevation Myocardial Infraction; PCI—percutaneous coronary intervention; MI—Myocardial Infraction; CABG—coronary artery bypass grafting; COPD—Chronic Obstructive Pulmonary Diseases.
The baseline procedural features of both study groups.
| Rotational | Shockwave | ||
|---|---|---|---|
| Syntax I score | 28.0 ± 7.5; | 23.3 ± 13.0 |
|
| Syntax II—PCI score | 35.8 ± 8.4 | 38.7 ± 14.8 | 0.489 |
| Syntax II PCI four year mortality | 9.6 [7.7–15.2] | 10.1 [5–34] | 0.876 |
| Syntax II—CABG score | 34.5 ± 9.0 | 38.3 ± 10.5 | 0.175 |
| Syntax II CABG year mortality | 11.5 [6.8–28.9] | 10.3 [6–20.1] | 0.414 |
| Radial Access | 15 (51.7%) | 12 (80.0%) | 0.287 |
| 6F Guide Catheter | 3 (10.3%) | 4 (26.7%) | 0.115 |
| 7F or larger Guide Catheter | 26 (89.6%) | 11 (73.3%) | 0.263 |
| Predilatation | 26 (89.6%) | 15 (100%) | 0.498 |
| Predilatation balloon diameter (mm) | 2.78 [2.5–3.0] | 3.24 [3–3.5] |
|
| Predilatation pressure (atm) | 21.2 ± 1.4 | 19.2 ± 1.4 |
|
| Single stent technique | 21 (72.4%) | 11 (73.3%) | 0.458 |
| Two stent bifurcation technique | 8 (27.6%) | 3 (20.0%) | 0.357 |
| Postdilatation—POT | 26 (89.6%) | 14 (93.3%) | 0.558 |
| Intravascular Guidance | 3 (10.3%) | 3 (20.0%) | 0.420 |
| Perforation | 3 (10.3%) | 0 (0%) | 0.327 |
| No-flow phenomenon | 1 (3.4%) | 0 (0%) | 0.561 |
| Administration of catecholamines | 2 (6.9%) | 2 (13.3%) | 0.420 |
| Acetylsalicylic Acid | 29 (100%) | 15 (100%) | 1 |
| Clopidogrel | 19 (65.6%) | 9 (60%) | 0.552 |
| Ticagrelol | 10 (34.4%) | 6 (40%) | 0.552 |
Abbreviations: PCI—percutaneous coronary intervention; CABG—coronary artery bypass grafting; POT—proximal optimization technique; bold text—statistically significant value.
Clinical follow-up data of both groups.
| Rotational | Shockwave | ||
|---|---|---|---|
| In hospital follow-up | |||
| MACE | 3 (10.3%) | 1 (6.7%) | 0.619 |
| Death | 3 (10.3%) | 1 (6.7%) | 0.619 |
| Myocardial infarction | 0 (0%) | 1 (6.7%) | 0.341 |
| Target vessel revascularization | 0 (0%) | 1 (6.7%) | 0.341 |
| Stent thrombosis | 0 (0%) | 1 (6.7%) | 0.341 |
| Cerebrovascular episodes | 0 (0%) | 0 (0%) | – |
| Stent restenosis | 0 (0%) | 0 (0%) | – |
| Any revascularization | 0 (0%) | 0 (0%) | – |
| Six Month follow-up | |||
| MACE | 5 (17.2%) | 2 (13.3%) | 0.807 |
| Death | 4 (13.7%) | 2 (13.3%) | 0.965 |
| Myocardial infarction | 1 (3.4%) | 1 (6.7%) | 0.619 |
| Target vessel revascularization | 0 (0%) | 1 (6.7%) | 0.151 |
| Stent thrombosis | 0 (0%) | 1 (6.7%) | 0.151 |
| Cerebrovascular episodes | 0 (0%) | 0 (0%) | – |
| Stent restenosis | 0 (0%) | 0 (0%) | – |
| Any revascularization | 2 (6.9%) | 0 (0%) | 0.413 |
Abbreviations: MACE—Major adverse cardiac events.